Product Description
Titanium dioxide (TiO2) is a natural oxide of the element titanium with low toxicity, and negligible biological effects. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26996620/)
Mechanisms of Action: UV Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous, Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Denmark | Ecuador | France | Hong Kong | India | Ireland | Israel | Italy | Malta | Morocco | New Zealand | Norway | Portugal | Sweden | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Orfagen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Egypt
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Dentin Sensitivity|Depressive Disorder, Treatment-Resistant
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12625001326482 |
ACTRN12625001326482 | P1 |
Not yet recruiting |
Depressive Disorder, Treatment-Resistant |
2026-12-01 |
2025-11-29 |
Treatments |
|
NCT06025084 |
Fadia Ali El-Sayed Shosha | P1 |
Completed |
Dentin Sensitivity |
2023-03-15 |
2023-09-07 |
Primary Endpoints|Treatments |